FDA approves new option amid COVID-19-spurred sedation drug shortages
The Food and Drug Administration this week approved dexmedetomidine hydrochloride in 0.9% sodium chloride injection for the sedation of initially intubated and mechanically ventilated patients in an intensive-care setting and of non-intubated patients prior to and/or during surgical and other procedures.
The drug helps address short supplies of sedation options due to the COVID-19 public health emergency. Side effects of the drug include low blood pressure, slow heart rate and dry mouth.
Related News Articles
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…